A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992 on ClinicalTrials.gov · last registry update 2026-04-30
Finished 9 October 2025, after enrolling 218 people. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 218
- Started
- 2024-04-02
- Primary completion
- 2025-10-09 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%]
Conditions studied
Obesity · Non-Alcoholic SteatoHepatitis (NASH)
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.